Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Statin-Induced Insulin Resistance Through Inflammasome Activation: Sailing Between Scylla and Charybdis

  1. Patricia Mitchell and
  2. André Marette⇑
  1. Department of Medicine, Faculty of Medicine, Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada
  1. Corresponding author: André Marette, andre.marette{at}criucpq.ulaval.ca.
Diabetes 2014 Nov; 63(11): 3569-3571. https://doi.org/10.2337/db14-1059
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Elevated LDL cholesterol is an independent risk factor for cardiovascular disease (CVD), and current clinical guidelines recommend aggressive reduction as the preferred course of treatment (1). Type 2 diabetes (T2D) also is a major and independent risk factor for development of CVD (2). A plethora of clinical data exists substantiating the beneficial effects of treatment with inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductases—commonly known as statins—on cardiovascular morbidity and mortality in both nondiabetic people and those with T2D (3). While statin therapy clearly reduces cardiovascular events, accumulating evidence indicates that statins also may confer increased risk for T2D (4). Recent analyses of both clinical trials and population-based cohort studies suggest that the cardiovascular benefits of statin therapy outweigh the risk of developing T2D (5,6). Nevertheless, findings that suggest increased incidence of T2D in some high-risk patients (e.g., those with elevated fasting glucose [5]) or in certain populations (e.g., postmenopausal women [7]) may call for greater caution in statin use, particularly at a time when its over-the-counter availability is being considered (8).

Given the overwhelming consensus from both meta-analyses and prospective studies that statin treatment can result in an increased risk of developing T2D, it is critical to identify the underlying causes of this unfavorable side effect. It has been suggested that statins increase T2D risk by impairing β-cell insulin secretion and promoting insulin resistance (9), but the precise molecular mechanisms are still unknown. Numerous studies have demonstrated intimate involvement of the innate immune system in both obesity and the pathogenesis of T2D (10,11). In recent years, pattern recognition receptors of the innate immune system, such as Toll-like receptors and Nod-like receptors (NLRs), have been increasingly recognized as links between immune function and metabolism (12,13). The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is the most thoroughly characterized of the inflammasomes. It has been shown to contain (among other activators) an NLR, the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) adaptor protein and caspase-1 (14). The NLRP3 inflammasome plays a central role in secretion of interleukin-1β (IL-1β) in response to various stimuli and therefore may prove to be a potential target for treatment in T2D. Indeed, it has been shown that subjects with the metabolic syndrome have increased activation of the NLRP3 inflammasome in adipose tissue macrophages (15). The clinical relevance of the NLRP3 inflammasome also is supported by recent data showing that T2D patients have elevated levels of the inflammasome proteins NLRP3 and ASC and increased caspase-1 activation prior to receiving treatment (16).

In this issue of Diabetes, Henriksbo et al. (17) provide evidence that various statins increase IL-1β secretion from macrophages through activation of the NLRP3 inflammasome. It is known that activation of the NLRP3 inflammasome requires priming (14). In the current report, none of the tested statins were able to stimulate IL-1β secretion without the presence of a priming agent, in this case the bacterial endotoxin lipopolysaccharide (LPS). Importantly, long-term treatment of obese mice with fluvastatin was found to promote insulin resistance in adipose tissue. Fluvastatin, in the presence of LPS priming, increased caspase-1 activity and IL-1β production in adipose tissue explants from wild-type mice, a result that was absent in NLRP3−/− fat explants. Glyburide, a known inflammasome inhibitor and antidiabetes drug, prevented statin-induced caspase-1 activity and adipose tissue insulin resistance. Given that adipose tissue is a mixture of cell types and that the NLRP3 inflammasome is thought to be expressed predominantly in nonadipose cells in fat, the requirement of IL-1β and/or caspase-1 activity for statin-induced insulin resistance was further investigated in 3T3-L1 adipocytes. These studies revealed that combined fluvastatin and LPS treatment induced caspase-1 activation and impaired insulin signaling but without any concomitant increase in IL-1β secretion. This suggests that adipocytes are unlikely to be the cellular source of IL-1β production in adipose tissue of obese mice. Although these data further implicate that caspase-1 activation is sufficient to impair insulin signaling in adipocytes, even in the absence of IL-1β, whether inhibition of inflammasome activation with glyburide could prevent statin-induced insulin resistance in this clonal adipocyte model was not investigated. Moreover, given that IL-1β was not the mediator of insulin resistance in these cells, the molecular mechanisms by which activation of the NLRP3 inflammasome by statins causes insulin resistance in fat cells remain elusive.

The new study by Henriksbo et al. (17) clearly shows that fluvastatin causes insulin resistance through activation of the NLRP3 inflammasome in murine adipose tissue explants. However, it remains to be seen whether statin therapy triggers the NLRP3 inflammasome in vivo and if it promotes insulin resistance in human adipose tissue. Future studies also should test whether statins induce inflammasome activation and insulin resistance in other metabolic tissues such as liver and skeletal muscle, as well as in pancreatic islets where NLRP3 inflammasome activation has been linked to enhanced IL-1β and T2D pathogenesis (18,19). Future work also should identify the priming “danger signals” that activate adipose NLRP3 inflammasome in obesity. Given the growing evidence that dysregulation of the gut microbiota leads to metabolic endotoxemia in obesity (20), it is tempting to conclude that LPS is the key priming agent (Fig. 1). However, it was found that LPS was not required for fluvastatin-mediated impairment of insulin signaling in fat explants (17), suggesting that other adipose-specific endogenous signals also may play a key role in priming the NLRP3 inflammasome in obesity. Indeed, several molecular triggers that are known to be elevated in the proinflammatory adipose tissue of obese subjects, such as saturated fatty acids, ceramides, and the products of hypoxic and necrotic fat cells, may all activate the NLRP3 inflammasome (13,14).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Working model for statin-induced NLRP3 inflammasome activation and insulin resistance. The beneficial outcomes of statin therapy for the prevention of CVD are indisputable, but statins have been shown to increase the risk for T2D. Lowering of plasma LDL cholesterol (Chol) levels through aggressive lipid-lowering therapy leads to a decrease in morbidity and mortality from CVD. The study of Henriksbo et al. (17) shows that statins, in the presence of the endotoxin LPS, activate the NLRP3 inflammasome in macrophages as well as in adipose tissue explants, which causes insulin resistance in fat. Based on this study, it is proposed that in the obese dyslipidemic patient, a gut dysbiosis–linked rise in circulating LPS may provide the priming event, potentially along with other endogenous adipose priming danger signals, leading to statin-induced NLRP3 inflammasome activation and the subsequent secretion of IL-1β. Whether this proinflammatory cytokine is the mediator of insulin resistance remains elusive. This proinflammatory effect of statins may offset some of the positive effects of lipid-lowering therapy. In the nonobese dyslipidemic patient, statin therapy also may potentially increase insulin resistance and T2D through modest inflammasome activation in fat or other insulin target tissues (not illustrated), but it remains to be shown whether LPS, or other priming danger signals such as oxidized cholesterol or cholesterol crystals, are implicated.

It also should be mentioned that activation of the NLRP3 inflammasome may be tissue-specific and greatly influenced by the type of statin used. It was recently reported that atorvastatin, but not rosuvastatin, downregulates the NLRP3 inflammasome in Japanese patients with coronary artery disease (21). Although this conclusion was based on determination of NLRP3, IL-1β, and IL-18 levels and not confirmed by caspase-1 activity measurements, these data suggest that not all statins may increase the NLRP3 inflammasome, at least in certain populations. In fact, these coronary artery disease patients were not obese, and this may be a key factor to consider for statin-induced activation of the inflammasome. More studies are warranted to determine the effect of statin therapy on NLRP3 inflammasome activation in diverse cohorts, especially in obese insulin-resistant subjects who are at greatly increased risk for T2D.

In conclusion, the work of Henriksbo et al. (17) strengthens the argument that we need to better understand the relationship between statin treatment and insulin resistance and its potential contribution to the increased T2D risk in patients under lipid-lowering therapy with this class of drugs. While activation of the NLRP3 inflammasome appears to be a key mechanism underlying this undesirable statin side effect, it is now critical to identify the molecular drivers of this inflammatory pathway in adipose tissue and other key metabolic and vascular tissues. Further elucidation of the mechanism of action could influence the next generation of statins by avoiding these adverse effects on the NLRP3 inflammasome while preserving their lipid-lowering action. This also may help design novel combination therapies in which statins are used together with drugs (e.g., glyburide) or nutritional treatments that aim to limit inflammasome activation. In this regard, it is interesting to note that a recent study revealed that omega-3 fatty acids are potent suppressors of the NLRP3 inflammasome in obese insulin-resistant mice fed a high-fat diet (22). Any strategies that would limit the side effects of statins on this inflammatory mechanism are of paramount clinical significance given the number of people prescribed this therapy and the typical duration of treatment.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 3742.

  • © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Baigent C,
    2. Blackwell L,
    3. Emberson J,
    4. et al.,
    5. Cholesterol Treatment Trialists’ (CTT) Collaboration
    . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681pmid:21067804
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Sarwar N,
    2. Gao P,
    3. Seshasai SR,
    4. et al.,
    5. Emerging Risk Factors Collaboration
    . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]. Lancet 2010;375:2215–2222pmid:20609967
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Kearney PM,
    2. Blackwell L,
    3. Collins R,
    4. et al.,
    5. Cholesterol Treatment Trialists’ (CTT) Collaborators
    . Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–125pmid:18191683
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Sattar N,
    2. Preiss D,
    3. Murray HM,
    4. et al
    . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742pmid:20167359
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Ridker PM,
    2. Pradhan A,
    3. MacFadyen JG,
    4. Libby P,
    5. Glynn RJ
    . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565–571pmid:22883507
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Corrao G,
    2. Ibrahim B,
    3. Nicotra F,
    4. et al
    . Statins and the risk of diabetes: Evidence from a large population-based cohort study. Diabetes Care 2014;37:2225–2232pmid:24969582
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Culver AL,
    2. Ockene IS,
    3. Balasubramanian R,
    4. et al
    . Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med 2012;172:144–152pmid:22231607
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Grabowski DC,
    2. Lakdawalla DN,
    3. Goldman DP,
    4. et al
    . The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood) 2012;31:2276–2285pmid:23048109
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Park ZH,
    2. Juska A,
    3. Dyakov D,
    4. Patel RV
    . Statin-associated incident diabetes: a literature review. Consult Pharm 2014;29:317–334pmid:24849689
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gregor MF,
    2. Hotamisligil GS
    . Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415–445pmid:21219177
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Donath MY,
    2. Shoelson SE
    . Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98–107pmid:21233852
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Schertzer JD,
    2. Tamrakar AK,
    3. Magalhães JG,
    4. et al
    . NOD1 activators link innate immunity to insulin resistance. Diabetes 2011;60:2206–2215pmid:21715553
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Vandanmagsar B,
    2. Youm YH,
    3. Ravussin A,
    4. et al
    . The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179–188pmid:21217695
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010;327:296–300
  15. ↵
    1. Esser N,
    2. L’homme L,
    3. De Roover A,
    4. et al
    . Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013;56:2487–2497pmid:24013717
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lee HM,
    2. Kim JJ,
    3. Kim HJ,
    4. Shong M,
    5. Ku BJ,
    6. Jo EK
    . Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013;62:194–204pmid:23086037
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Henriksbo BD,
    2. Lau TC,
    3. Cavallari JF,
    4. et al
    . Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014;63:3742–3747pmid:24917577
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Masters SL,
    2. Dunne A,
    3. Subramanian SL,
    4. et al
    . Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010;11:897–904pmid:20835230
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Zhou R,
    2. Tardivel A,
    3. Thorens B,
    4. Choi I,
    5. Tschopp J
    . Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136–140pmid:20023662
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Cani PD,
    2. Osto M,
    3. Geurts L,
    4. Everard A
    . Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279–288pmid:22572877
    OpenUrlCrossRefPubMed
  21. ↵
    1. Satoh M,
    2. Tabuchi T,
    3. Itoh T,
    4. Nakamura M
    . NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin Sci (Lond) 2014;126:233–241pmid:23944632
    OpenUrlCrossRefPubMed
  22. ↵
    1. Yan Y,
    2. Jiang W,
    3. Spinetti T,
    4. et al
    . Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013;38:1154–1163pmid:23809162
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes: 63 (11)

In this Issue

November 2014, 63(11)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Statin-Induced Insulin Resistance Through Inflammasome Activation: Sailing Between Scylla and Charybdis
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Statin-Induced Insulin Resistance Through Inflammasome Activation: Sailing Between Scylla and Charybdis
Patricia Mitchell, André Marette
Diabetes Nov 2014, 63 (11) 3569-3571; DOI: 10.2337/db14-1059

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Statin-Induced Insulin Resistance Through Inflammasome Activation: Sailing Between Scylla and Charybdis
Patricia Mitchell, André Marette
Diabetes Nov 2014, 63 (11) 3569-3571; DOI: 10.2337/db14-1059
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
  • There Is Something About Insulin Granules
  • Metabolic Flexibility of Mitochondria Plays a Key Role in Balancing Glucose and Fatty Acid Metabolism in the Diabetic Heart
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.